• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[头颈部鳞状细胞癌复发与远处转移的治疗：2015年美国临床肿瘤学会会议要点]

[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].

作者信息

Bußmann L, Busch C-J, Knecht R

机构信息

Klinik und Poliklinik für Hals-, Nasen- und Ohrenheilkunde, Kopf-Hals-Chirurgie und Onkologie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.

出版信息

HNO. 2015 Sep;63(9):620-4. doi: 10.1007/s00106-015-0055-0.

DOI:10.1007/s00106-015-0055-0
PMID:26319430
Abstract

This year also saw a great number of phase II and III studies presented at the ASCO Annual Meeting, in which new drugs (monoclonal antibodies, small molecules) were investigated as an alternative to or in combination with established mono- and polychemotherapy in patients with recurrences or distance metastases from head and neck squamous cell carcinoma (R/M-HNSCC). The studies now presented here describe the different concepts being applied to drug-based treatment of R/M-HNSCC and illustrate the variety of therapeutic approaches to treatment of recurrences and metastases.

摘要

今年，也有大量的II期和III期研究在ASCO年会上发表，其中研究了新药（单克隆抗体、小分子药物）作为头颈部鳞状细胞癌复发或远处转移（R/M-HNSCC）患者既定单药和多药化疗的替代方案或联合用药方案。本文展示的研究描述了应用于R/M-HNSCC药物治疗的不同概念，并阐明了治疗复发和转移的多种治疗方法。

相似文献

1
[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].[头颈部鳞状细胞癌复发与远处转移的治疗：2015年美国临床肿瘤学会会议要点]
HNO. 2015 Sep;63(9):620-4. doi: 10.1007/s00106-015-0055-0.
2
[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the ASCO Meeting 2016].[头颈部鳞状细胞癌复发和远处转移的治疗：2016年美国临床肿瘤学会会议要点]
HNO. 2016 Oct;64(10):723-30. doi: 10.1007/s00106-016-0235-6.
3
[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2018 ASCO meeting].[头颈部鳞状细胞癌复发和远处转移的治疗：2018年美国临床肿瘤学会会议要点]
HNO. 2018 Dec;66(12):907-912. doi: 10.1007/s00106-018-0580-8.
4
[Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].[复发性或转移性头颈部鳞状细胞癌的治疗：2014年美国临床肿瘤学会会议要点]
HNO. 2014 Nov;62(11):787-92. doi: 10.1007/s00106-014-2927-0.
5
[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting].[头颈部鳞状细胞癌复发与远处转移的治疗：2019年美国临床肿瘤学会会议要点]
HNO. 2019 Dec;67(12):898-904. doi: 10.1007/s00106-019-00773-4.
6
[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].[头颈部肿瘤的初始治疗研究结果：2016年美国临床肿瘤学会年会要点]
HNO. 2016 Oct;64(10):717-22. doi: 10.1007/s00106-016-0243-6.
7
[Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].[头颈部肿瘤的免疫治疗：2015年美国临床肿瘤学会会议要点]
HNO. 2015 Sep;63(9):612-9. doi: 10.1007/s00106-015-0054-1.
8
[Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].[头颈部肿瘤的免疫治疗研究：2016年美国临床肿瘤学会年会亮点]
HNO. 2016 Oct;64(10):708-16. doi: 10.1007/s00106-016-0238-3.
9
Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens.长春瑞滨/西妥昔单抗治疗至少两种化疗方案治疗后进展的复发性/转移性头颈部鳞状细胞癌患者的 II 期研究。
Oral Oncol. 2010 Nov;46(11):818-21. doi: 10.1016/j.oraloncology.2010.08.013.
10
Afatinib in squamous cell carcinoma of the head and neck.阿法替尼治疗头颈部鳞状细胞癌。
Expert Opin Pharmacother. 2016 Jun;17(9):1295-301. doi: 10.1080/14656566.2016.1183647. Epub 2016 May 19.

引用本文的文献

1
[Importance of interdisciplinary collaboration for optimal treatment of orbital tumors].[跨学科协作对眼眶肿瘤最佳治疗的重要性]
HNO. 2019 Jul;67(7):528-533. doi: 10.1007/s00106-019-0659-x.
2
[Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].[头颈部肿瘤的临床前模型：肿瘤微环境中细胞和分子耐药机制的评估]
HNO. 2016 Dec;64(12):860-869. doi: 10.1007/s00106-016-0276-x.

本文引用的文献

1
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.阿法替尼对比甲氨蝶呤用于铂类治疗后进展的复发性或转移性头颈部鳞状细胞癌患者的二线治疗（LUX-Head & Neck 1）：一项开放标签、随机、III 期研究。
Lancet Oncol. 2015 May;16(5):583-94. doi: 10.1016/S1470-2045(15)70124-5. Epub 2015 Apr 16.
2
Metastasis occurring eleven years after diagnosis of human papilloma virus-related oropharyngeal squamous cell carcinoma.在人乳头瘤病毒相关的口咽鳞状细胞癌诊断十一年后发生转移。
Ecancermedicalscience. 2014 Nov 13;8:480. doi: 10.3332/ecancer.2014.480. eCollection 2014.
3
Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.LUX-头颈1研究的原理与设计：一项针对铂类治疗后进展的复发和/或转移性头颈部鳞状细胞癌患者，比较阿法替尼与甲氨蝶呤的随机III期试验。
BMC Cancer. 2014 Jun 28;14:473. doi: 10.1186/1471-2407-14-473.
4
HPV positive squamous cell carcinoma of the oropharynx. Are we observing an unusual pattern of metastases?口咽人乳头瘤病毒阳性鳞状细胞癌。我们是否正在观察到一种不寻常的转移模式？
Head Neck Pathol. 2012 Sep;6(3):336-44. doi: 10.1007/s12105-012-0355-6. Epub 2012 Apr 15.
5
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer.培美曲塞和贝伐珠单抗治疗复发性或转移性头颈部癌患者的 II 期临床试验。
J Clin Oncol. 2011 Mar 20;29(9):1140-5. doi: 10.1200/JCO.2010.33.3591. Epub 2011 Feb 22.
6
Human papillomavirus and survival of patients with oropharyngeal cancer.人乳头瘤病毒与口咽癌患者的生存。
N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
7
Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships.头颈部鳞状细胞癌组织匀浆中的血管生成生长因子：表达模式、预后相关性及相互关系
Cancer Sci. 2009 Jul;100(7):1210-8. doi: 10.1111/j.1349-7006.2009.01158.x. Epub 2009 Mar 31.
8
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
9
Strong immunohistochemical expression of vascular endothelial growth factor predicts overall survival in head and neck squamous cell carcinoma.血管内皮生长因子的强免疫组化表达可预测头颈部鳞状细胞癌的总生存期。
Ann Surg Oncol. 2007 Dec;14(12):3558-65. doi: 10.1245/s10434-007-9632-0. Epub 2007 Oct 11.
10
Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma.血管内皮生长因子免疫组化表达及肿瘤血管生成在头颈部鳞状细胞癌中的预后意义
J Cancer Res Clin Oncol. 2005 Sep;131(9):624-30. doi: 10.1007/s00432-005-0003-6. Epub 2005 Oct 20.